Skip to main content

Table 2 Medman trial data for respondents to the DCE survey (continued)

From: What, who and when? Incorporating a discrete choice experiment into an economic evaluation

  Trial groups Intervention subgroups
Intervention
N = 364
P vala Control
N = 190
P vala Still receiving at 24 months
N = 188
P vala Not receiving at 24 months
N = 176
P vala
Baseline 12-month follow-up   Baseline 12-month follow-up   Baseline 12-month follow-up   Baseline 12-month follow-up  
Costs
  559.12   336.23   327.00   303.40  
 Costs mean 1579.40 1568.20 0.90 1242.40 1277.59 0.68 1653.94 1617.20   1499.77 1515.85  
SD 1323.11 1472.54 1182.63 926.10 1299.74 1510.42 1346.76 1433.45
 Difference in costs −11.20   35.20    −36.73 0.77   16.08 0.89
559.65 336.79 325.25 303.32
Outcomes
 Appropriate treatment score mean 4.20 4.26 0.55 4.30 4.40 0.51 4.15 4.27 0.44 4.25 4.25 1.00
SD 0.94 1.03 0.87 1.01 0.97 0.94 0.92 1.12
 SF-6D Score mean 0.71 0.71 0.55 0.73 0.73 0.66 0.70 0.69 0.14 0.72 0.73 0.28
SD 0.14 0.15 0.14 0.15 0.14 0.14 0.14 0.15
 EQ-5D Score mean 0.73 0.74 0.11 0.73 0.74 0.24 0.73 0.71 0.59 0.73 0.74 0.28
SD 0.24 0.26 0.24 0.27 0.23 0.27 0.26 0.25
 Satisfaction score mean 42.36 48.30 <0.01 42.90 44.74 0.86 45.74 52.38 0.02 39.26 43.67 <0.01
SD 9.89 15.75 9.45 17.34 9.68 15.78 9.07 14.49
  1. aDifferences between baseline and 24-month follow-up were tested using paired t test statistics